RPG Active Pharma Acquires Raghava Life Sciences’ API Business For Up To ₹135 Crore
The Pharmaceutical/API Company has been steadily building out its API business rather than letting it grow on its own timeline. Through its subsidiary, RPG Active Pharma, the company has now agreed to take over a Hyderabad-based manufacturing facility that comes with established regulatory approvals and a fairly wide product portfolio already in place. It’s the second such deal in quick succession, and taken together, the pattern looks less like opportunistic buying and more like a company trying to reach scale on a set schedule.
Shares of RPG Life Sciences Ltd are trading at Rs. 2,645.90, up 3.16 percent on Thursday. The stock touched the intraday high of Rs. 2,648.80 after opening at Rs. 2,596.90 before slipping to a low of Rs. 2,583.10. The company commands a market capitalization of Rs. 4,366.13 crore.
Building API Platform
RPG Life Sciences informed stock exchanges on September 2 that its API arm, RPG Active Pharma, will acquire the API and intermediates business of Raghava Life Sciences. The acquisition will be executed via a slump sale for an aggregate consideration of up to Rs. 135 crore. The Raghava plant sits on nine acres near Hyderabad and already carries WHO-GMP and EU-GMP certifications, no small thing, since getting a facility to that standard usually takes years, not months.
It comes with 29 API molecules on its books, 22 of them commercial and seven still working through development. This is RPGAP’s second deal this year after it picked up Actis Generics, so the pattern is becoming hard to miss: closing conditions and regulatory sign-off aside, RPG seems to be building an API platform through acquisition rather than waiting on organic capacity additions.
Integration Real Test
Look at this deal alongside the Actis purchase and a clearer picture emerges. Actis gave RPGAP backward-integrated intermediates manufacturing out of Vizag; Raghava adds scale and a much wider commercial product basket, plus the kind of regulatory paperwork CEP, EU Written Confirmation, KDMF that takes real time to build from scratch. Management calls this a buy-and-build strategy, which is a fair description, though it’s worth noting that two acquisitions inside a single year is an aggressive pace even by consolidation standards. The question investors will naturally ask is whether RPGAP can actually integrate what it’s bought before it goes shopping again.
That’s really where the real test lies, not in the deal itself. RPGAP has pointed to a revenue potential of around Rs. 200 crore for the Raghava plant at full utilisation, but that number assumes the synergies of shared capacity, product transfers between sites, backward integration paying off in cost terms. None of that happens automatically just because two facilities now sit under the same balance sheet.
On financing, the company has been upfront that this is being paid for out of the equity it recently raised with InvAscent rather than fresh borrowing, so the debt profile stays clean. That said, running three manufacturing sites profitably is a different exercise than running one, and how well RPGAP manages that transition will likely matter more to earnings over the next couple of years than the acquisition price itself.
Financial Performance
Looking at the quarterly results of RPG Life Sciences Limited, the company’s consolidated revenue from operations increased by 15.78 percent YOY, from Rs. 168.92 crore in Q1 FY26 to Rs. 195.69 crore in Q1 FY27, and grew by 10.6 percent QoQ from Rs. 176.89 crore in Q4 FY26.
In Q1 FY27, the company’s consolidated net profit increased by 17.00 percent YOY, reaching Rs. 30.76 crore compared to Rs. 26.29 crore during the same period last year. As compared to Q4 FY26, the net profit has increased by 2.87 percent, from Rs. 29.90 crore.
The basic earnings per share increased by 16.98 percent and stood at Rs. 18.60 as against Rs. 15.90 recorded in the same quarter in the previous year, FY2026.
Macro Economic Perspective
Viewed in a broader context, this transaction aligns with a significant structural transformation currently unfolding across India’s API sector. A fairly deliberate push to cut reliance on Chinese imports and build manufacturing that can hold its own on both compliance and cost. Government support for API self-sufficiency has helped, and demand for generics in areas like diabetes and cardiovascular care isn’t going anywhere anytime soon.
For mid-sized players without the scale to compete purely on price, buying capacity has become a more practical route than building it from the ground up which is essentially what RPG is doing here. Whether this pays off depends less on the strategy, which is sound enough on paper, and more on execution: turning newly added EU-GMP capacity into steady export volume rather than letting it sit half-utilised, which has tripped up more than one Indian API consolidation story before.
Company Overview
RPG Life Sciences is an integrated pharmaceutical company operating across branded formulations, generics, and synthetic APIs in India and abroad. Its API subsidiary, RPG Active Pharma, has been actively consolidating the space first with Actis Generics, now with Raghava Life Sciences while backed by pharma-focused investor InvAscent, aiming to build a scaled, backward-integrated API business over the next few years.
